🇺🇸 FDA
Patent

US 10392368

Pyrazolo and triazolo bicyclic compounds as JAK kinase inhibitors

granted A61KA61K31/416A61P

Quick answer

US patent 10392368 (Pyrazolo and triazolo bicyclic compounds as JAK kinase inhibitors) held by Theravance Biopharma R&D IP, LLC expires Mon Aug 22 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Theravance Biopharma R&D IP, LLC
Grant date
Tue Aug 27 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 22 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
46
CPC classes
A61K, A61K31/416, A61P, A61P1/00, A61P17/00